{"product_id":"vstm-bcg-matrix","title":"(VSTM) Verastem, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Verastem, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the analysis, so you can inspect the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvutometinib plus defactinib, recurrent LGSOC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvutometinib plus defactinib is Verastem, Inc.'s Star asset and lead program, with recurrent LGSOC as a rare niche and limited options. In the phase 2 RAMP 201 study, the combo produced a 44% objective response rate and median progression-free survival of 22 months, making it the pipeline's main value driver. It is the clearest shot at a future market leader and the core of Verastem, Inc.'s growth case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVS-6766 RAF\/MEK clamp, 1 asset platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVS-6766 is Verastem, Inc.'s core Star asset: a dual RAF\/MEK clamp that blocks MEK kinase activity and also stops RAF from phosphorylating MEK, giving it clear differentiation in the KRAS\/MAPK oncology space.\u003c\/p\u003e\n\u003cp\u003eThat mechanism supports a broad combo strategy and makes the program highly strategic as Verastem's 1-asset platform, with outsized value if late-stage data convert into approval.\u003c\/p\u003e\n\u003cp\u003eIts BCG \"Star\" profile fits a high-growth, high-focus asset that can anchor future revenue, not just pipeline optionality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 201, 2-part randomized study\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 201 is an adaptive, multicenter, randomized, open-label study of VS-6766 alone and with defactinib in recurrent low-grade serous ovarian cancer. It is the main late-stage evidence driver for Verastem, Inc., so it sits in the Stars bucket of the BCG matrix. The trial’s two-part design supports clearer efficacy readouts and a stronger path to value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDefactinib, oral FAK inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDefactinib is Verastem’s lead partner drug: an oral small-molecule focal adhesion kinase inhibitor used across avutometinib-based regimens. Its biggest value is combination depth, since the pair won U.S. FDA approval in 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer, giving the franchise a sharper commercial profile.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral FAK inhibitor\u003c\/li\u003e\n\u003cli\u003eCore combo backbone\u003c\/li\u003e\n\u003cli\u003e2025 FDA-approved regimen\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChugai rights, development to commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem’s Chugai deal gives Chugai rights to develop, commercialize, and manufacture VS-6766-based products, which is strong external validation for the program. A reported upfront payment of $40 million and potential milestones of up to $600 million-plus show real pharma interest in the asset. That kind of partner backing lifts VS-6766’s BCG \"Star\" case because it expands global reach without Verastem funding all execution alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChugai holds development, commercialization, and manufacturing rights.\u003c\/li\u003e\n\u003cli\u003eUpfront cash: $40 million.\u003c\/li\u003e\n\u003cli\u003eMilestones: up to $600 million-plus.\u003c\/li\u003e\n\u003cli\u003eSupports global upside for VS-6766.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s FDA Win Sets Up a Real Revenue Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.'s Star is avutometinib plus defactinib in recurrent LGSOC: 44% objective response rate and 22-month median PFS in RAMP 201 support strong growth. The pair won U.S. FDA approval in 2025, giving the franchise real revenue potential. Chugai also paid $40 million upfront, with up to $600 million-plus in milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar asset\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvutometinib plus defactinib\u003c\/td\u003e\n\u003ctd\u003e44% ORR; 22-month PFS; 2025 FDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChugai deal\u003c\/td\u003e\n\u003ctd\u003e$40 million upfront; up to $600 million-plus milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eVerastem, Inc. BCG Matrix shows where to invest, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix snapshot for Verastem, Inc. to quickly spot growth, cash, and risk hotspots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eVerastem, Inc. Reference Sources provide a clear, credible trail that supports fast due diligence and more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 approved products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. has 0 approved products, so it has no true cash cow in the classic BCG sense. As an emerging biopharma, it is still in the cash-burning development stage, with revenue from approved drugs at zero and spending tied to R\u0026amp;D and clinical work. That means its portfolio is not generating stable cash; it is still consuming capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChugai licensing economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChugai is Verastem, Inc.'s closest asset-linked cash stream, but it is still a support line, not a full franchise. License deals can bring upfront cash, milestones, and royalties, and royalties in biopharma often run in the low-single-digit to mid-teens range; that means the upside is real, but it stays contingent on partner progress, not Verastem's own sales engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer FAK agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025\/2026, Verastem’s FAK program reflects partner-sourced R\u0026amp;D: the Pfizer license gives access to built assets while limiting upfront discovery spend. That makes it a capital-light funding model, but not a true Cash Cow because value depends on milestone and royalty economics, not steady product sales. It lowers internal burn, but it does not yet generate durable operating cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAmgen collaboration support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc.’s Amgen collaboration helps fund the RAMP 203 combo study, so it fits a Cash Cows label only in a support sense, not as a real product cow. The value is partner-backed development, which can ease R\u0026amp;D cash pressure and lower dilution risk. It does not produce steady sales like an approved drug, so the cash impact stays episodic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports RAMP 203 development\u003c\/li\u003e\n\u003cli\u003eReduces funding strain\u003c\/li\u003e\n\u003cli\u003eNot recurring product cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-dilutive partner funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. has no commercial product sales, so non-dilutive partner funding is its main cash stabilizer. These deals help cover R\u0026amp;D while the company advances late-stage trials, so they act more like financing support than a mature product cash engine.\u003c\/p\u003e\n\n\u003cp\u003eIn its latest filings, Verastem still reported operating losses and continued to fund studies in 2025, making partner cash a key offset to trial spend. That matters because each dollar of external support reduces pressure on equity raises and helps extend runway.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner cash supports clinical development.\u003c\/li\u003e\n\u003cli\u003eNo product revenue, so cash stays fragile.\u003c\/li\u003e\n\u003cli\u003eFunding is non-dilutive, not sales-driven.\u003c\/li\u003e\n\u003cli\u003eIt bridges R\u0026amp;D until commercialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Burns Cash, It Doesn’t Harvest It\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. has no true Cash Cows because it has 0 approved products and no product revenue. Its only cash support comes from partner deals and collaborations, which help fund R\u0026amp;D but do not create steady operating cash. So the portfolio still burns cash, it does not harvest it.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eCash Cow?\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003e0 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner funding\u003c\/td\u003e\n\u003ctd\u003ePartial\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical assets\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003ctd\u003eCash burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eVerastem, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Verastem, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No placeholders or demo pages—just the full, professionally formatted report. Once purchased, it’s ready for immediate download and use in your analysis, presentations, or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 marketed brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. had 0 marketed brands, and no approved commercial product was disclosed, so it does not have a classic Dog in the BCG sense. The Dog quadrant is effectively empty because the Company is still pre-commercial and has no weak, declining brand to classify. That makes the point simple: no product sales means no legacy dog asset to manage or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e0 recurring product revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. had 0 recurring product revenue in FY2025 and FY2026, so there is no low-growth sales base to harvest. Without an approved product, there is also no brand with declining market share to divest. This is a company-stage gap, not a mature-product decline; Verastem reported no product sales while it kept funding pipeline work with about $144 million in cash and equivalents at year-end 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo legacy commercial franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. has no legacy commercial franchise to drag on the Dogs side of the BCG Matrix because it is still an oncology development company, not a mature drug seller. Its value is tied to experimental assets, so the main risk is pipeline failure, not declining sales from older products. That also means there is no aging marketed drug base generating the kind of low-growth, low-share cash flow that usually defines a Dog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo high-volume mature indication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. has no clear \"dog\" asset because its disclosed programs sit in rare or biomarker-defined cancers, not in a large, mature mass market. Its lead focus includes low-grade serous ovarian cancer, which is only about 1% to 2% of ovarian cancers, so the franchise is clinically important but not high-volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo exhausted consumer-style market\u003c\/li\u003e\n\u003cli\u003eRare, biomarker-driven cancer focus\u003c\/li\u003e\n\u003cli\u003eLGSC is ~1%-2% of ovarian cancers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNo divestiture candidate disclosed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVerastem, Inc. has no disclosed divestiture candidate because it has no marketed product generating weak returns; the business is still centered on clinical-stage assets and partnership structures. In BCG terms, any underperforming program would be a pipeline call, not a classic \"dog\" tied to revenue drag. With no commercial franchise, the main capital use remains R\u0026amp;D, not a low-return product line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo public commercial \"dog\" is identified.\u003c\/li\u003e\n\u003cli\u003eAssets remain in trials and partnerships.\u003c\/li\u003e\n\u003cli\u003eWeak programs would be pipeline cuts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem Has No “Dog” Franchise—Just Pipeline Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. has no true Dog in the BCG Matrix because it reported 0 marketed brands and 0 product revenue in FY2025 and FY2026. With no approved commercial product, there is no weak legacy franchise to harvest, divest, or fix. The core risk is pipeline execution, not declining sales. Year-end 2025 cash and equivalents were about $144 million, supporting R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\/FY2026\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed brands\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-end cash\u003c\/td\u003e\n\u003ctd\u003e$144M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDog status\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 202, KRAS and BRAF NSCLC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 202 is a Phase 2 study of VS-6766 plus defactinib in KRAS- and BRAF-mutant non-small cell lung cancer after platinum and immune checkpoint therapy. NSCLC is the largest lung cancer segment, with about 2.48 million new cases worldwide in 2022, so the addressable pool is sizable. But Verastem, Inc. still has low share here because the asset is investigational and not yet approved. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRAMP 203, LUMAKRAS combination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRAMP 203 is Verastem, Inc.’s Phase 1\/2 test of VS-6766 with Amgen’s LUMAKRAS (sotorasib), so it fits a Question Mark in the BCG Matrix: high scientific interest, but no proven commercial scale yet. In targeted KRAS oncology, early-stage combos can create upside, but until efficacy and safety data mature, the revenue case stays uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader KRAS-mutant solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc. can reach more than one KRAS-driven setting because KRAS mutations show up in about 25% of solid tumors, so the biology gives real upside beyond ovarian cancer. That makes this a question mark with strong growth optionality. \u003c\/p\u003e\n\u003cp\u003eStill, each new tumor type must prove response, safety, and durability in its own cohort before it can win share. In KRAS-heavy cancers like NSCLC, KRAS G12C alone appears in about 13% of cases, but broad use needs better data than a mutation label. \u003c\/p\u003e\n\u003cp\u003eSo the asset can move from question mark to star only if late-stage readouts show clear, durable benefit and clean tolerability. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDefactinib combination expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDefactinib is still a Question Mark in Verastem, Inc.'s BCG Matrix because it works as a combination backbone, not as a standalone seller. Its 2025 FDA-accepted role came only with avutometinib in KRAS-mutated recurrent low-grade serous ovarian cancer, so growth depends on combo data holding up across more tumors. If new trials expand beyond one approved use, this could shift fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 approval supports combo value.\u003c\/li\u003e\n\u003cli\u003eStandalone market remains unproven.\u003c\/li\u003e\n\u003cli\u003eBroader tumor data is the key catalyst.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVS-6766 global expansion path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChugai’s rights to develop and commercialize VS-6766 in Japan point to a wider global runway, not just a single-region story. The asset can scale, but only if late-stage clinical data and regulators back it. Until then, it stays a question mark, not a cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJapan rights widen market reach\u003c\/li\u003e\n\u003cli\u003eValue still hinges on trial success\u003c\/li\u003e\n\u003cli\u003eNo durable franchise cash flow yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerastem’s Oncology Bets: Big Upside, Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVerastem, Inc.'s Question Marks are still early, high-upside oncology assets: RAMP 202 and RAMP 203 are both investigational, so share and revenue are not proven yet. The prize is big because KRAS mutations appear in about 25% of solid tumors, but each tumor type still needs its own win.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\/2026 status\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 202\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003eNo approval; NSCLC is huge but unproven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAMP 203\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eEarly combo; no scale yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDefactinib\u003c\/td\u003e\n\u003ctd\u003e2025 combo role\u003c\/td\u003e\n\u003ctd\u003eValue depends on more tumor data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235162595593,"sku":"vstm-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vstm-bcg-matrix.webp?v=1785735649","url":"https:\/\/dcfanalyst.com\/products\/vstm-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}